Target intelligence / Profile preview

Adaptor related protein complex 1 subunit sigma 2 (AP1S2)

Target
AP1S2
Molecular classification
Other (Adaptor protein complex subunit), Protein sorting machinery, Member of the adaptin family, Component of clathrin-associated AP-1 complex
01

Overview

Adaptor related protein complex 1 subunit sigma 2 (AP1S2) encodes the small sigma-2 subunit of the clathrin-associated adaptor protein complex 1 (AP-1). The AP-1 complex regulates vesicle formation and protein sorting at the trans-Golgi network and endosomes by recognizing sorting signals in transmembrane proteins and recruiting clathrin to the membrane surface[1][3]. It is essential for proper cell function, particularly in neurons, and disruption of its function via mutation can cause syndromic X-linked mental retardation and related neurodevelopmental disorders such as Pettigrew syndrome[1][2][7]. AP1S2 is not considered a classical therapeutic target but is implicated in the molecular machinery that governs protein sorting and vesicular trafficking in human cells.

Other names
AP-1 complex subunit sigma-2AP1S2SIGMA1BSigma1B-adaptinAdaptor-related protein complex 1 subunit sigma-1BClathrin assembly protein complex 1 sigma-1B small chainGolgi adaptor HA1/AP1 adaptin sigma-1B subunitDC22MRX59MRXS21MRXS5MRXSFPGSSigma 1B subunit of AP-1 clathrinAdapter-related protein complex 1 sigma-1B subunitMental Retardation, X-Linked 59Pettigrew X-Linked Mental Retardation Syndrome
02

Mechanism of action

Null. No established drugs target AP1S2 directly.

03

Biological functions

Protein sorting at the trans-Golgi network (TGN) and/or endosomesRecruitment of clathrin to membranesRecognition of sorting signals in transmembrane cargo moleculesFormation of coated vesicles in intracellular traffickingMaintenance of neuronal protein distribution (somatodendritic sorting)
04

Disease associations

Neurodevelopmental disorder: Pettigrew syndrome (X-linked mental retardation with neurological abnormalities such as choreoathetosis, hydrocephalus, Dandy–Walker malformation, seizures, and abnormal brain iron/calcium deposition)Basal ganglia calcification, idiopathic, 6Mental retardation syndromes (MRX59, MRXS21, MRXS5, MRXSF)
05

Safety considerations

Mutations lead to serious neurodevelopmental disorders, but there are no established therapeutic safety concerns as AP1S2 is not a direct drug target

Beyond the preview

Go deeper on Adaptor related protein complex 1 subunit sigma 2 (AP1S2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adaptor related protein complex 1 subunit sigma 2 (AP1S2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call